Tenon Medical (TNON) investor relations material

Company overview and business model

• Medical-device business focused on sacro-pelvic disorders; offers Catamaran and SImmetry systems for sacroiliac joint fusion.

• Catamaran received FDA clearance in 2018 and launched nationally in October 2022; SImmetry was acquired in August 2025.

• Strategy combines inferior-posterior and lateral approaches, with products designed for minimally invasive access and joint fusion.

Financial performance and metrics

• Haskell & White’s audit report on FY2025 and FY2024 financial statements included an explanatory paragraph expressing substantial doubt about ability to continue as a going concern.

• Significant additional capital may be needed in the near future to continue planned operations; historical financing has included equity, warrants and convertible securities.

Use of proceeds and capital allocation

• No proceeds from selling-stockholder resales; cash warrant exercises may generate up to $4,308,510 gross at the current $5.02 exercise price.

• Net cash-exercise proceeds are intended for working capital and general corporate purposes; a risk disclosure also identifies capital expenditures, with management retaining broad discretion.

• Resale registration expenses are borne by the issuer; the selling stockholder bears commissions, discounts and similar sale expenses.